A Research Study of How Oral Semaglutide Tablets Work in Healthy People Who Are Chinese
Primary Purpose
Healthy Volunteers, Diabetes Mellitus, Type 2
Status
Completed
Phase
Phase 1
Locations
China
Study Type
Interventional
Intervention
Oral semaglutide
Placebo
Sponsored by

About this trial
This is an interventional treatment trial for Healthy Volunteers
Eligibility Criteria
Inclusion Criteria:
- Chinese male or female, aged 18-55 years (both inclusive) at the time of signing informed consent.
- Body weight equal to or above 54.0 kg
- Body mass index (BMI) between 20.0 and 24.9 kg/m^2 (both inclusive)
- Considered to be generally healthy based on the medical history, physical examination, and the results of vital signs, ECG and clinical laboratory tests performed during the screening visit, as judged by the investigator.
Exclusion Criteria:
- Female who is pregnant, breast-feeding or intends to become pregnant or is of child-bearing potential and not using highly effective contraceptive methods
- History of pancreatitis (acute or chronic) as declared by the subject.
- Family or personal history of multiple endocrine neoplasia type 2 (MEN2) or medullary thyroid carcinoma (MTC) as declared by the subject.
- History or presence of malignant neoplasms within the last 5 years (except basal and squamous cell skin cancer and in-situ carcinomas) as declared by the subject.
- History of major surgical procedures involving the stomach potentially affecting absorption of trial product (e.g., subtotal and total gastrectomy, sleeve gastrectomy, gastric bypass surgery) as declared by the subject.
- Smoker (defined as a subject who is smoking equal to or more than 1 cigarette or the equivalent per day).
- Unable or unwilling to refrain from smoking and use of nicotine substitute products during the inpatient periods, as judged by the investigator.
- Any blood draw in excess of 25 mL in the past month, or donation of blood or plasma in excess of 400 mL within the 3 months preceding screening.
Sites / Locations
- Novo Nordisk Investigational Site
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
Placebo Comparator
Arm Label
Oral semaglutide
Placebo
Arm Description
Outcomes
Primary Outcome Measures
AUC0-24h,sema,SS, area under the semaglutide concentration-time curve during a dosing interval (0-24 hours) at steady state
h*nmol/L
Secondary Outcome Measures
Cmax,sema,SS, maximum observed semaglutide plasma concentration during a dosing interval (0-24 hours) at steady state
nmol/L
tmax,sema,SS, time to maximum observed semaglutide plasma concentration during a dosing interval (0-24 hours) at steady state
h
CL/Fsema,SS, total apparent clearance of semaglutide at steady state
L/h
Ctrough,sema,SS, trough semaglutide plasma concentration at steady state
nmol/L
t½,sema,SS, terminal half-life of semaglutide at steady state
h
Vss/Fsema, apparent volume of distribution of semaglutide at steady state
L
MRTsema,SS, mean residence time of semaglutide at steady state
h
Rtheor,sema,SS, theoretical accumulation index, which is defined as [1/(1-Exp (-λZ,sema,SS*24h))], where λZ,sema,SS=log(2)/t½,sema,SS
Index value
Change in body weight from baseline
kg
Change in fasting plasma glucose from baseline
mmol/l
Number of treatment-emergent adverse events
Count
Number of treatment-emergent hypoglycaemic episodes
Count
Full Information
1. Study Identification
Unique Protocol Identification Number
NCT04016974
Brief Title
A Research Study of How Oral Semaglutide Tablets Work in Healthy People Who Are Chinese
Official Title
A Multiple-dose, Single-centre, Randomised, Double-blind, Placebo-controlled Trial to Investigate the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Oral Semaglutide in Healthy Chinese Subjects
Study Type
Interventional
2. Study Status
Record Verification Date
February 2023
Overall Recruitment Status
Completed
Study Start Date
October 8, 2019 (Actual)
Primary Completion Date
January 23, 2021 (Actual)
Study Completion Date
February 26, 2021 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Novo Nordisk A/S
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No
5. Study Description
Brief Summary
This study looks at the way a new medicine tablet called semaglutide moves in and throughout the body over time. It will also look at if the medicine is safe and the body can accept it. The new medicine is planned to treat diabetes. The aim of the study is to see how semaglutide tablets work in healthy people who are Chinese. Participants will either get oral semaglutide tablets or placebo (dummy) tablets - which treatment is decided by chance. The tablet form of semaglutide is a new medicine that cannot be prescribed. Doctors can prescribe semaglutide as an injection only. It is for the treatment of diabetes in some countries. Participants will get 1 tablet per day for 12 weeks (84 days). Participants will get 1 tablet a day to take with up to half a glass of water (maximum 120 mL). Participants must take the tablet first thing in the morning on an empty stomach (water is allowed until 2 hours before taking the tablet). After taking the tablet, participants must not eat or drink anything for at least 30 minutes. After 30 minutes, they can have their first meal of the day and take any other medicines they may need, such as birth control tablets, routine vitamins and use of paracetamol at times.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Healthy Volunteers, Diabetes Mellitus, Type 2
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 1
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Masking Description
Sponsor staff involved in the clinical trial is masked according to company standard procedures
Allocation
Randomized
Enrollment
32 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Oral semaglutide
Arm Type
Experimental
Arm Title
Placebo
Arm Type
Placebo Comparator
Intervention Type
Drug
Intervention Name(s)
Oral semaglutide
Intervention Description
Semaglutide tablets once daily as follows: 3 mg for the first treatment period (day 1-28), followed by 7 mg in the second treatment period (day 29-56), followed by 14 mg in the third treatment period (day 57-84)
Intervention Type
Drug
Intervention Name(s)
Placebo
Intervention Description
Placebo tablets once daily throughout the treatment period (day 1 to 84)
Primary Outcome Measure Information:
Title
AUC0-24h,sema,SS, area under the semaglutide concentration-time curve during a dosing interval (0-24 hours) at steady state
Description
h*nmol/L
Time Frame
After the last dose of oral semaglutide at dose levels of 3 mg on day 28 and 7 mg on day 56, and after the last 3 daily doses of oral semaglutide at dose level 14 mg on day 82, 83 and 84
Secondary Outcome Measure Information:
Title
Cmax,sema,SS, maximum observed semaglutide plasma concentration during a dosing interval (0-24 hours) at steady state
Description
nmol/L
Time Frame
After the last dose of oral semaglutide at dose levels of 3 mg on day 28 and 7 mg on day 56, and after the last 3 daily doses of oral semaglutide at dose level 14 mg on day 82, 83 and 84
Title
tmax,sema,SS, time to maximum observed semaglutide plasma concentration during a dosing interval (0-24 hours) at steady state
Description
h
Time Frame
After the last dose of oral semaglutide at dose levels of 3 mg on day 28 and 7 mg on day 56, and after the last 3 daily doses of oral semaglutide at dose level 14 mg on day 82, 83 and 84
Title
CL/Fsema,SS, total apparent clearance of semaglutide at steady state
Description
L/h
Time Frame
After the last dose of oral semaglutide at dose levels of 3 mg on day 28 and 7 mg on day 56, and after the last 3 daily doses of oral semaglutide at dose level 14 mg on day 82, 83 and 84
Title
Ctrough,sema,SS, trough semaglutide plasma concentration at steady state
Description
nmol/L
Time Frame
After the last 3 daily doses of oral semaglutide administration at 3, 7 and 14 mg dose levels on day 27-29, 55-57 and 83-85
Title
t½,sema,SS, terminal half-life of semaglutide at steady state
Description
h
Time Frame
After the last dose of oral semaglutide 14 mg on day 84
Title
Vss/Fsema, apparent volume of distribution of semaglutide at steady state
Description
L
Time Frame
After the last dose of oral semaglutide 14 mg on day 84
Title
MRTsema,SS, mean residence time of semaglutide at steady state
Description
h
Time Frame
After the last dose of oral semaglutide 14 mg on day 84
Title
Rtheor,sema,SS, theoretical accumulation index, which is defined as [1/(1-Exp (-λZ,sema,SS*24h))], where λZ,sema,SS=log(2)/t½,sema,SS
Description
Index value
Time Frame
After the last dose of oral semaglutide 14 mg on day 84
Title
Change in body weight from baseline
Description
kg
Time Frame
Day 1, day 85
Title
Change in fasting plasma glucose from baseline
Description
mmol/l
Time Frame
Day 1, day 85
Title
Number of treatment-emergent adverse events
Description
Count
Time Frame
From the time of first dosing (day 1) until completion of the follow-up visit (day 119-121)
Title
Number of treatment-emergent hypoglycaemic episodes
Description
Count
Time Frame
From the time of first dosing (day 1) until completion of the follow-up visit (day 119-121)
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
55 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria:
Chinese male or female, aged 18-55 years (both inclusive) at the time of signing informed consent.
Body weight equal to or above 54.0 kg
Body mass index (BMI) between 20.0 and 24.9 kg/m^2 (both inclusive)
Considered to be generally healthy based on the medical history, physical examination, and the results of vital signs, ECG and clinical laboratory tests performed during the screening visit, as judged by the investigator.
Exclusion Criteria:
Female who is pregnant, breast-feeding or intends to become pregnant or is of child-bearing potential and not using highly effective contraceptive methods
History of pancreatitis (acute or chronic) as declared by the subject.
Family or personal history of multiple endocrine neoplasia type 2 (MEN2) or medullary thyroid carcinoma (MTC) as declared by the subject.
History or presence of malignant neoplasms within the last 5 years (except basal and squamous cell skin cancer and in-situ carcinomas) as declared by the subject.
History of major surgical procedures involving the stomach potentially affecting absorption of trial product (e.g., subtotal and total gastrectomy, sleeve gastrectomy, gastric bypass surgery) as declared by the subject.
Smoker (defined as a subject who is smoking equal to or more than 1 cigarette or the equivalent per day).
Unable or unwilling to refrain from smoking and use of nicotine substitute products during the inpatient periods, as judged by the investigator.
Any blood draw in excess of 25 mL in the past month, or donation of blood or plasma in excess of 400 mL within the 3 months preceding screening.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Clinical Reporting Anchor and Disclosure (1452)
Organizational Affiliation
Novo Nordisk A/S
Official's Role
Study Director
Facility Information:
Facility Name
Novo Nordisk Investigational Site
City
Beijing
State/Province
Beijing
ZIP/Postal Code
100730
Country
China
12. IPD Sharing Statement
Plan to Share IPD
Yes
IPD Sharing Plan Description
According to the Novo Nordisk disclosure commitment on novonordisk-trials.com
IPD Sharing URL
http://novonordisk-trials.com
Learn more about this trial
A Research Study of How Oral Semaglutide Tablets Work in Healthy People Who Are Chinese
We'll reach out to this number within 24 hrs